Chinese medicine for prostate cancer: Do they influence the androgen receptor?
Other conference paper

Full Text

Other information
AbstractAndrogen receptor (AR), located on X chromosome (q11-12), is a 110kDa nuclear receptor that, upon activation by androgens, mediates transcription of target genes to modulate growth and differentiation of prostate epithelial cells. AR is also the major therapeutic target for the treatment of prostate cancer (PCa). Treatment with anti-androgens, used either singly or combined with other therapies, is highly effective to stabilize the PCa from further progression effectively blocking the endogenous androgen actions via their direct competitive blockade on the AR in prostate cancer cells. Many lines of clinical evidence suggest that Chinese medicine has unique advantage for the treatment of PCa. Radix Codonopsis (RC, 黨參), Herba Epimedii (HE, 淫羊霍) are among the herbs commonly used in clinical practice for the treatment of PCa. However, whether these herbs have effect on PCa and the underlying action mechanism of these herbs on PCa remains largely unknown. In the present study, we explored the anti-proliferation of the selected Chinese herbs by employing the LNCaP and 22Rv1 cell lines. And the AR-related protein expressions were measured by using Western Blot or Elisa Kit to elucidate whether the selected Chinese herbs could influence the AR and PSA expression. Our results showed the RC and other twenty herbs did not show significant cytotoxicity to bother LNCaP and 22Rv1 cells at the concentration up to 200 ug/mL. Interestingly, RC (黨參), HE (淫羊霍) and RO (麥冬) could significantly increase the protein expressions of AR and PSA in LNCaP and 22Rv1 cells, while DCL (石斛), CR (川芎) and RA (黃芪) could obviously decrease the protein expression of AR and PSA in LNCaP and 22Rv1 cells. These results indicated that DCL (石斛), CR (川芎) and RA (黃芪) might inhibit the progression of PCa by inhibiting the AR and PSA expression, while RC (川芎), HE (淫羊霍) and RO (麥冬) might promote the development of PCa. Further in vivo studies are needed to confirm the effects of these drugs on PCa.
All Author(s) ListZhen-Biao Zhang, Yan-Fang Xian, Siu-Po Ip, Zhi-Xiu Lin
Name of ConferenceThe 15th International Postgraduate Symposium on Chinese Medicine (IPSCM)
Start Date of Conference16/08/2019
End Date of Conference16/08/2019
Place of ConferenceHong Kong
Country/Region of ConferenceHong Kong
LanguagesEnglish-United Kingdom

Last updated on 2020-20-11 at 12:56